


PRODUCT INFORMATION



Leflunomide

Item No. 14860

CAS Registry No.: 75706-12-6
Formal Name: 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide
Synonyms: HW 486, SU 101
MF: C₁₂H₉F₃N₂O₂
FW: 270.2
Purity: ≥98%
UV/Vis.: λ_{max}: 206, 262 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Leflunomide is supplied as a crystalline solid. A stock solution may be made by dissolving the leflunomide in the solvent of choice. Leflunomide is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of leflunomide in these solvents is approximately 20, 16.7, and 25 mg/ml, respectively.

Leflunomide is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, leflunomide should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Leflunomide has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Leflunomide is a synthetic isoxazol and a prodrug form of A-771726 (Item No. 14404), a dihydroorotate dehydrogenase inhibitor.¹ Leflunomide inhibits *de novo* pyrimidine synthesis to regulate T lymphocyte progression through the cell cycle. It inhibits proliferation and activation of T cells when used at concentrations of 25 and 100 μM, respectively, for naïve and memory CD4⁺ T cells.² It also reduces the production of Th1 effector cells and increases differentiation of Th2 cells *in vitro* and in splenocytes isolated from KLH-immunized mice. Leflunomide (35 mg/kg per day) reduces and prevents inflammation in a proteoglycan-induced mouse model of rheumatoid arthritis.³ Formulations containing leflunomide have been used in the treatment of active rheumatoid arthritis.

References

1. Breedveld, F.C. and Dayer, J.M. Leflunomide: Mode of action in the treatment of rheumatoid arthritis. *Ann. Rheum. Dis.* **59(11)**, 841-849 (2000).
2. Dimitrova, P., Skapenko, A., Herrmann, M.L., *et al.* Restriction of *de novo* pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. *J. Immunol.* **169(6)**, 3392-3399 (2002).
3. Glant, T.T., Mikecz, K., Bartlett, R.R., *et al.* Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide. *Immunopharmacology* **23(2)**, 105-116 (1992).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/15/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM